Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

Similar articles for PubMed (Select 24758301)

1.

Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion.

Notsu M, Yamaguchi T, Okazaki K, Tanaka K, Ogawa N, Kanazawa I, Sugimoto T.

Endocrinology. 2014 Jul;155(7):2402-10. doi: 10.1210/en.2013-1818. Epub 2014 Apr 23.

PMID:
24758301
2.

Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis.

Okazaki K, Yamaguchi T, Tanaka K, Notsu M, Ogawa N, Yano S, Sugimoto T.

Calcif Tissue Int. 2012 Oct;91(4):286-96. doi: 10.1007/s00223-012-9641-2. Epub 2012 Aug 18.

PMID:
22903508
3.

Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic reticulum stress.

Tanaka K, Yamaguchi T, Kaji H, Kanazawa I, Sugimoto T.

Biochem Biophys Res Commun. 2013 Aug 30;438(3):463-7. doi: 10.1016/j.bbrc.2013.07.126. Epub 2013 Aug 7.

PMID:
23933252
4.
5.

Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.

Tanikawa T, Okada Y, Tanikawa R, Tanaka Y.

J Vasc Res. 2009;46(6):572-80. doi: 10.1159/000226225. Epub 2009 Jun 30.

PMID:
19571577
6.

Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2.

Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, Sugimoto T, Chihara K.

J Biol Chem. 2004 Sep 24;279(39):40267-75. Epub 2004 May 18.

7.

TGF-β-related mechanisms of bone destruction in multiple myeloma.

Matsumoto T, Abe M.

Bone. 2011 Jan;48(1):129-34. doi: 10.1016/j.bone.2010.05.036. Epub 2010 Jun 1. Review.

PMID:
20570621
8.

Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.

Nakamura A, Ly C, Cipetić M, Sims NA, Vieusseux J, Kartsogiannis V, Bouralexis S, Saleh H, Zhou H, Price JT, Martin TJ, Ng KW, Gillespie MT, Quinn JM.

Bone. 2007 Feb;40(2):305-15. Epub 2006 Oct 13.

PMID:
17049328
9.

Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.

Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S.

Horm Metab Res. 2012 Nov;44(12):891-5. doi: 10.1055/s-0032-1321878. Epub 2012 Aug 3.

PMID:
22864903
10.

Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro.

Yokosuka K, Park JS, Jimbo K, Yoshida T, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata K.

Spine (Phila Pa 1976). 2007 May 15;32(11):E337-9.

PMID:
17495767
11.

Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells.

Huang H, Zhao N, Xu X, Xu Y, Li S, Zhang J, Yang P.

Cell Prolif. 2011 Oct;44(5):420-7. doi: 10.1111/j.1365-2184.2011.00769.x.

PMID:
21951285
12.

Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.

Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T.

PLoS One. 2009;4(4):e5275. doi: 10.1371/journal.pone.0005275. Epub 2008 Apr 16.

13.

Nell-1, a key functional mediator of Runx2, partially rescues calvarial defects in Runx2(+/-) mice.

Zhang X, Ting K, Bessette CM, Culiat CT, Sung SJ, Lee H, Chen F, Shen J, Wang JJ, Kuroda S, Soo C.

J Bone Miner Res. 2011 Apr;26(4):777-91. doi: 10.1002/jbmr.267.

14.

Identification of the GATA factor TRPS1 as a repressor of the osteocalcin promoter.

Piscopo DM, Johansen EB, Derynck R.

J Biol Chem. 2009 Nov 13;284(46):31690-703. doi: 10.1074/jbc.M109.052316. Epub 2009 Sep 15.

15.
17.

Advanced glycation end products affect growth and function of osteoblasts.

Franke S, Rüster C, Pester J, Hofmann G, Oelzner P, Wolf G.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):650-60. Epub 2011 Aug 31.

PMID:
21906430
18.

Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation.

Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Galléa S, Stiot V, Blanchet AM, Courtois B, Baron R, Rawadi G.

Bone. 2001 Oct;29(4):323-30.

PMID:
11595614
19.

Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME, Lan HY.

Am J Pathol. 2004 Apr;164(4):1389-97.

20.

TGF-β/BMP signaling pathway is involved in cerium-promoted osteogenic differentiation of mesenchymal stem cells.

Liu DD, Zhang JC, Zhang Q, Wang SX, Yang MS.

J Cell Biochem. 2013 May;114(5):1105-14. doi: 10.1002/jcb.24451.

PMID:
23150386
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk